Overview

A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

Status:
Terminated

Trial end date:
2021-10-13

Target enrollment:

Participant gender:

Summary

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to-Moderate Ulcerative Colitis

Phase:

Phase 2

Details

Lead Sponsor:

Seres Therapeutics, Inc.

Treatments:

Vancomycin